Therapeutic insights into “awakening the sleeping angel” in mutant p53-expressing human tumors: MiR-3666 increases the expression of tumor suppressor p53 homologue TAp73 and induces regression of p53-mutated human tumors via down regulation of its target gene, 17/December/2016, 11.14 pm

Molecular therapy for triple-negative breast tumors: MiR-663 increases the levels of cell cycle inhibitor, p27, inhibits pro-survival pathways mediated by c-Myc, and inhibits the progression of triple-negative breast cancer via up-regulation of its target gene, 17/December/2016, 10.59 pm
December 17, 2016
MiRNA-based PD-1 pathway blockade for Human cancer therapy: MiR-660 decreases the expression of Glycogen synthase kinase-3β, increases transcription factor T-bet expression, decreases the abundance of co-inhibitory receptor PD-1 on the cell surface of Cytotoxic-T-cells, increases cytotoxic T lymphocyte function and augments anti-tumor activity, via up-regulation of its target gene, 17/December/2016, 11.20 pm
December 17, 2016
Show all

From Significance of the study to Public health relevance:

Given that: (1) Cancer suppressor p53 is mutated in more than 50% of human cancers of different tissue origin; (2) p53 pathway is altered in about 80% of tumors.; (3) our understanding is incomplete in terms of molecular targets and the oncogenic/malignant pathways involved in mutant p53-overexpressing tumors; (4) cancer causes the highest economic loss compared to all the known causes of death worldwide; and (5) cancer causes the considerable economic loss worldwide, there is an urgent need to find: (i) a cheaper alternative to the existing expensive drugs; (ii) a side-effect-free natural product-based drug; and (iii) a way to effectively treat and stall metastatic progression and relapse of mutant p53-overexpressing human cancers.


From therapeutic strategy to Research Findings:

This study suggests a therapeutic strategy for stalling the progression of p53-deficient/deleted or mutant-p53 expressing human metastatic cancers. By activating tumor suppressor p53’s unmutated or rarely mutated “homologous protein such as TAp73” in p53-deficient or mutant-p53 expressing human metastatic cancers, one can stall them.

MiR-3666, by decreasing the expression of its target genes, it may increase the expression of tumor suppressor TAp73. Thereby, it may inhibit the migration and invasion of metastatic cancer cells expressing mutant-p53.


Therapeutic opportunity:

Given the ability of MiR-3666 to induce the expression of TAp73 in p53-mutated human tumors, pharmacological formulations encompassing “MiR-3666 or its activators” may be used to inhibit the progression of p53-mutated invasive metastatic tumors.

price-100

Together, this study suggests an MiRNA-based therapy for p53-mutated metastatic human tumors.[easy_payment currency=”USD”]


Details of the research findings

Idea Proposed/Formulated by: Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Amount: $100#

Undisclosed mechanistic information: How MiR-3666 increases the expression of TAp73

For purchase and payment details, you may reach us at admin@genomediscovery.org

#Research cooperation


References:

Web: http://genomediscovery.org or http://newbioideas.com

Citation: Boominathan, L., Therapeutic insights into “awakening the sleeping angel” in mutant p53-expressing human tumors: MiR-3666 increases the expression of tumor suppressor p53 homologue TAp73 and induces regression of p53-mutated human tumors via down regulation of its target gene, 17/December/2016, 11.14 pm, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite drop us a line at info@genomediscovery.org

Comments are closed.